# Argatroban for Preventing Occlusion and Restenosis After Extracranial Vertebral Artery Stenting

> **NCT01980316** · PHASE4 · COMPLETED · sponsor: **Xinfeng Liu** · enrollment: 114 (actual)

## Conditions studied

- CVD

## Interventions

- **DRUG:** Argatroban
- **DRUG:** non-argatroban treated group

## Key facts

- **NCT ID:** NCT01980316
- **Lead sponsor:** Xinfeng Liu
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04
- **Primary completion:** 2011-08
- **Final completion:** 2013-07
- **Target enrollment:** 114 (ACTUAL)
- **Last updated:** 2015-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01980316

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01980316, "Argatroban for Preventing Occlusion and Restenosis After Extracranial Vertebral Artery Stenting". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01980316. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*